Drug
Market For Type 2 Diabetes Will Reach $20.5 Billion
In 2012
9/15/2003
Decision Resources, Inc.,
one of the world's leading research and advisory
firms focusing on pharmaceutical and health care
issues, finds that the drug market for type 2
diabetes will reach $20.5 billion in 2012,
representing a robust 2002-2012 annual growth rate
of 8%. According to the new Pharmacor report
entitled Type 2 Diabetes, driving the expansion of
this market are emerging agents that offer novel
mechanisms of action, such as the glucagon-like
peptide-1 (GLP-1) analogues, and improvements on
existing therapies, such as inhaled insulin and
dual-acting peroxisome proliferator-activated
receptor (PPAR) agonists.
"Between 2006 and 2012, dual-acting PPAR
agonists and GLP-1 analogues will capture
significant shares of the type 2 diabetes
market," said Carole Gleeson, analyst at
Decision Resources. "Many physicians consider
dual-acting PPAR agonists and inhaled insulin to be
promising agents, but they are concerned about
safety issues and await more clinical trial data.
The experts also recognize the potential of GLP-1
analogues, which will be strong competitors to
existing insulin secretagogues."
About Type 2 Diabetes
The International Diabetes Foundation recently
warned that type 2 diabetes had become a global
pandemic and one of the most challenging public
health problems of the 21st century. It is a
progressive disease of metabolic deregulation
characterized by insulin resistance and impaired
insulin secretion. Prevalence of this complex
disease soared in the United States in the past
decade and is expected to increase rapidly in the
near future. The enormous size of the patient
population and the limitations of existing therapies
in reducing severe complications and altering
disease progression represent vast, untapped
commercial opportunity.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on
primary and secondary research conducted by Decision
Resources' on-staff experts. Each comprehensive
study assesses a host of market-impacting factors
and analyzes the commercial outlook for drugs in
research and development. Cardium, Cognos, Immune
and Inflammatory Disorders, Infectious Disease,
Metabolic Disorders, Psychiatric Disorders, and
Onkos concentrate on specific therapeutic areas.
Mosaic covers high-interest disease states. Type 2
Diabetes is a Metabolic Disorders study.
About Decision Resources
Decision Resources is a world leader in research
publications, advisory services, and consulting
designed to help clients shape strategy, allocate
resources, and master their chosen markets. The
company has provided strategic information services
for more than 30 years, and assesses international
pharmaceutical and health care industry trends.
Visit Decision Resources at http://www.decisionresources.com/.
All company, brand, or product names contained in
this document may be trademarks or registered
trademarks of their respective holders.
CONTACT: Elizabeth Marshall of Decision
Resources, Inc., +1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
|
